Xue Mei(薛 梅，Dept Hematol，Gener Hosp PLA Air Force，Beijing 100142)…∥Chin J Transplant.－2011，32(8).－488 ～491

Efficacy of rituximab－containing regimens on post－transplantation lymphoproliferative disorder following haploidentical hematopoietic stem cell trans-plantatio: reor f 3 css

Xue Mei(薛 梅，Dept Hematol，Gener Hosp PLA Air Force，Beijing 100142)…∥Chin J Transplant.－2011，32(8).－488 ～491

ObjectiveTo evaluate the efficacy of rituximabcontaining regimens on post－ transplantation lymphoproliferative disorder(PTLD)following haploidentical hematopoietic stem cell transplantation(HSCT).MethodsThe clinical data of 3 cases of PTLD after haploidentical HSCT were analyzed retrospectively.Time to development of PTLD ranged from 57 to 164 days after HSCT.The main symptoms included fever，superficial lymph node enlargement.Epstein－Parr virus(EBV)－positive B － cell PTLD was，diagnosed by biopsy of lymph node.Management of 3 patients consisted of withdraw of immunosuppressive treatment，anti － viral therapy，rituximab(375 mg/m2，per week for four weeks)monotherapy or chemotherapy plus rituximab.ResultsAll the patients recovered after treatment.ConclusionPTLD is a serious complication of HSCT especially haploidentical HSCT.Rituximab－containing regimens are potentially effective，well－ tolerated with mild toxicity and can improve the prognosis of PTLD following haploidentical HSCT.8 refs.

(Authors)